JP2023517644A5 - - Google Patents
Info
- Publication number
- JP2023517644A5 JP2023517644A5 JP2022554681A JP2022554681A JP2023517644A5 JP 2023517644 A5 JP2023517644 A5 JP 2023517644A5 JP 2022554681 A JP2022554681 A JP 2022554681A JP 2022554681 A JP2022554681 A JP 2022554681A JP 2023517644 A5 JP2023517644 A5 JP 2023517644A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062987191P | 2020-03-09 | 2020-03-09 | |
| US62/987,191 | 2020-03-09 | ||
| US202063073900P | 2020-09-02 | 2020-09-02 | |
| US63/073,900 | 2020-09-02 | ||
| PCT/US2021/021572 WO2021183563A1 (en) | 2020-03-09 | 2021-03-09 | Coronavirus vaccine compositions and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023517644A JP2023517644A (ja) | 2023-04-26 |
| JPWO2021183563A5 JPWO2021183563A5 (https=) | 2024-03-18 |
| JP2023517644A5 true JP2023517644A5 (https=) | 2024-03-18 |
Family
ID=77671984
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554681A Pending JP2023517644A (ja) | 2020-03-09 | 2021-03-09 | コロナウイルスワクチン組成物及び方法 |
| JP2022554368A Pending JP2023519173A (ja) | 2020-03-09 | 2021-03-09 | 免疫応答を誘導するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554368A Pending JP2023519173A (ja) | 2020-03-09 | 2021-03-09 | 免疫応答を誘導するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US11759515B2 (https=) |
| EP (2) | EP4117720A4 (https=) |
| JP (2) | JP2023517644A (https=) |
| AU (2) | AU2021233816A1 (https=) |
| CA (2) | CA3171231A1 (https=) |
| TW (1) | TW202200605A (https=) |
| WO (2) | WO2021183563A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10383952B2 (en) | 2016-12-21 | 2019-08-20 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| US10526284B2 (en) * | 2016-12-21 | 2020-01-07 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| WO2021183563A1 (en) | 2020-03-09 | 2021-09-16 | Arcturus Therapeutics, Inc. | Coronavirus vaccine compositions and methods |
| CA3172489A1 (en) | 2020-03-23 | 2021-09-30 | Amit KHANDHAR | Nanoemulsion compositions and methods for delivery of nra |
| US12558415B2 (en) * | 2020-04-14 | 2026-02-24 | The Regents Of The University Of California | Broad-spectrum multi-antigen pan-coronavirus vaccine |
| EP3901261A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
| WO2022011332A2 (en) * | 2020-07-10 | 2022-01-13 | Engimata, Inc | Immunogenic composition forming a vaccine, and a method for its manufacture |
| US12178921B2 (en) | 2020-08-14 | 2024-12-31 | Arcturus Therapeutics, Inc. | Method of lyophilizing lipid nanoparticles |
| SE544840C2 (en) * | 2020-09-28 | 2022-12-13 | Stora Enso Oyj | Method for the preparation of a bio-based carbon foam |
| JP2023546175A (ja) | 2020-10-14 | 2023-11-01 | ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド | 脂質ナノ粒子製造の方法及びそれに由来する組成物 |
| IL303195A (en) | 2020-11-25 | 2023-07-01 | Akagera Medicines Inc | Lipid nanoparticles for delivery of nucleic acids and related methods of use |
| US20220356212A1 (en) * | 2021-03-26 | 2022-11-10 | Nanogen Pharmaceutical Biotechnology JSC | Modified spike protein and method of treatment |
| TW202313967A (zh) * | 2021-07-30 | 2023-04-01 | 美商亞克圖羅斯醫療公司 | Ｒｎａ疫苗 |
| MX2024002726A (es) | 2021-09-03 | 2024-03-20 | CureVac SE | Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos. |
| WO2023044505A2 (en) * | 2021-09-20 | 2023-03-23 | Cyanvac Llc | Piv5-based coronavirus vaccines and methods of use thereof |
| EP4405372A4 (en) | 2021-09-22 | 2026-01-14 | Hdt Bio Corp | SARS-CoV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE |
| JP2024535354A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | がん治療組成物およびその使用 |
| EP4404919A4 (en) | 2021-09-22 | 2025-08-20 | Hdt Bio Corp | DRIED NANOPARTICLE COMPOSITIONS |
| KR20240096468A (ko) | 2021-09-22 | 2024-06-26 | 에이치디티 바이오 코포레이션 | 감염병에 대한 rna 백신 |
| US20250228926A1 (en) * | 2021-10-07 | 2025-07-17 | Global Life Sciences Solutions Canada Ulc | Rna vaccine lipid nanoparticles |
| EP4426266A4 (en) * | 2021-11-03 | 2025-11-05 | Arcturus Therapeutics Inc | LIPID FORMULATIONS CONTAINING NUCLEIC ACIDS AND METHODS OF TREATMENT OF CYSTIC FIBROSIS |
| WO2023079472A2 (en) * | 2021-11-03 | 2023-05-11 | Kashiv Biosciences, Llc | Multicistron expression vector for covid-19 vaccine |
| US11510975B1 (en) * | 2021-11-29 | 2022-11-29 | Replicate Bioscience, Inc. | Compositions and methods for inducing ESR1, PI3K, HER2, and HER3 immune responses |
| US20250090653A1 (en) * | 2021-11-29 | 2025-03-20 | Entos Pharmaceuticals, Inc. | Sars cov-2 vaccine, associated polynucleotides, and methods of use |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US20250041238A1 (en) * | 2021-12-23 | 2025-02-06 | Etherna Immunotherapies Nv | METHOD FOR LAGRE-SCALE PRODUCTION OF LARGE-SIZE LNPs |
| CN118613493A (zh) * | 2022-01-05 | 2024-09-06 | 螺旋纳米技术公司 | 包含α-因子前原序列的组合物及其用途 |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CN116916891A (zh) * | 2022-02-07 | 2023-10-20 | Seqirus公司 | 自我复制rna和其用途 |
| CN116768987A (zh) * | 2022-03-09 | 2023-09-19 | 中生复诺健生物科技(上海)有限公司 | 编码新型冠状病毒S蛋白的mRNA疫苗 |
| WO2023205644A1 (en) * | 2022-04-19 | 2023-10-26 | Replicate Bioscience, Inc. | Modified western equine encephalitis viruses and uses thereof |
| CN114557971B (zh) * | 2022-04-25 | 2023-05-23 | 康希诺生物股份公司 | 一种核酸-脂质纳米颗粒的冷冻干燥保护剂及其制备方法和应用 |
| US12084703B2 (en) | 2022-05-12 | 2024-09-10 | SunVax mRNA Therapeutics Inc. | Synthetic self-amplifying mRNA molecules with secretion antigen and immunomodulator |
| CN117070464A (zh) * | 2022-05-16 | 2023-11-17 | 上海行深生物科技有限公司 | 蛋白包裹自复制rna及其制备方法 |
| EP4531819A2 (en) * | 2022-05-25 | 2025-04-09 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| WO2024089229A1 (en) * | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
| US12186388B2 (en) * | 2022-11-02 | 2025-01-07 | Centre For Virology, Vaccinology And Therapeutics Limited | Interferon-producing universal sarbecovirus vaccines, and uses thereof |
| JP2026503735A (ja) * | 2023-01-31 | 2026-01-29 | アークトゥルス セラピューティクス， インコーポレイテッド | 四価インフルエンザワクチンのための方法及び組成物 |
| KR20250153298A (ko) | 2023-03-08 | 2025-10-24 | 큐어백 에스이 | 핵산 전달을 위한 신규의 지질 나노입자 제형 |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025104023A1 (en) * | 2023-11-13 | 2025-05-22 | Ziphius Nv | MODIFIED ALPHAVIRAL nsP3 |
| WO2025103803A1 (en) | 2023-11-13 | 2025-05-22 | CureVac SE | Immunotherapy against neuronal and brain tumors |
| TW202539706A (zh) * | 2023-11-14 | 2025-10-16 | 大陸商上海瑞宏迪醫藥有限公司 | 一種脂質奈米粒的製備方法和應用 |
| GB202400648D0 (en) * | 2024-01-17 | 2024-02-28 | Uea Enterprises Ltd | Protein replacement therapy |
| WO2025189168A1 (en) * | 2024-03-08 | 2025-09-12 | SunVax mRNA Therapeutics Inc. | Methods for cascade amplifications of therapeutic payloads (catp) & compositions for cancer immunotherapies and gene therapy |
| US20260002196A1 (en) * | 2024-07-01 | 2026-01-01 | New England Biolabs, Inc. | Programmable Cleavage of RNA |
| JP7657411B1 (ja) * | 2025-01-23 | 2025-04-07 | 医療法人すぎやま内科 | 乳がん細胞の増殖抑制剤及び乳がん治療剤 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003023026A1 (en) | 2001-09-06 | 2003-03-20 | Alphavax, Inc. | Alphavirus replicon vector systems |
| CN1791678A (zh) | 2003-03-20 | 2006-06-21 | 阿尔法瓦克斯公司 | 改进的甲病毒复制子和辅助构建体 |
| EP1751289B1 (en) | 2004-05-18 | 2009-01-14 | Alphavax, Inc. | Tc-83-derived alphavirus vectors, particles and methods |
| US20090104226A1 (en) | 2004-05-21 | 2009-04-23 | Novartis Vaccines And Diagnostics Inc. | Alphavirus Vectors for Respiratory Pathogen Vaccines |
| US7332322B2 (en) | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| UA101597C2 (uk) | 2006-02-27 | 2013-04-25 | Зе Боард Оф Регентс Оф Зе Універсіті Оф Тексас Сістем | Псевдоінфекційний флавівірус та його використання |
| EP2049665A2 (en) | 2006-07-28 | 2009-04-22 | Applera Corporation | Dinucleotide mrna cap analogs |
| WO2008119827A1 (en) * | 2007-04-02 | 2008-10-09 | Fit Biotech Oy | Transreplicase constructs |
| DK2947149T3 (en) | 2007-06-21 | 2018-06-06 | Alphavax Inc | ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION |
| WO2009058911A2 (en) | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Preparation and isolation of 5' capped mrna |
| JP5627464B2 (ja) * | 2007-11-26 | 2014-11-19 | ノバルティス アーゲー | アルファウイルス粒子を生成する方法 |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| AU2009238175C1 (en) | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
| NZ589495A (en) | 2008-05-23 | 2012-06-29 | Fit Biotech Oy | Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant |
| CN104119242B (zh) | 2008-10-09 | 2017-07-07 | 泰米拉制药公司 | 改善的氨基脂质和递送核酸的方法 |
| WO2010048536A2 (en) | 2008-10-23 | 2010-04-29 | Alnylam Pharmaceuticals, Inc. | Processes for preparing lipids |
| HUE037082T2 (hu) | 2008-11-10 | 2018-08-28 | Arbutus Biopharma Corp | Új lipidek és készítmények terápiás hatóanyagok szállítására |
| EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| KR20180094137A (ko) | 2009-05-05 | 2018-08-22 | 알닐람 파마슈티칼스 인코포레이티드 | 지질 조성물 |
| MX342785B (es) | 2009-06-10 | 2016-10-12 | Alnylam Pharmaceuticals Inc | Formulacion mejorada de lipido. |
| EP2519266B1 (en) | 2009-12-31 | 2017-07-26 | Medigen, Inc. | Infectious dna vaccines against chikungunya virus |
| SG186085A1 (en) | 2010-06-03 | 2013-01-30 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
| RS63817B1 (sr) | 2010-07-06 | 2023-01-31 | Glaxosmithkline Biologicals Sa | Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| HUE026646T2 (en) | 2010-07-06 | 2016-07-28 | Glaxosmithkline Biologicals Sa | Preferred liposomes containing lipids of PKA value for delivery of RNA |
| PL2591114T3 (pl) * | 2010-07-06 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Immunizacja dużych ssaków małymi dawkami rna |
| EP2590625B1 (en) * | 2010-07-06 | 2017-09-20 | GlaxoSmithKline Biologicals SA | Cationic oil-in-water emulsions |
| RS63890B1 (sr) | 2010-08-31 | 2023-02-28 | Glaxosmithkline Biologicals Sa | Mali lipozomi za isporuku rnk koja kodira imunogen |
| PT3970742T (pt) | 2010-08-31 | 2022-06-27 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para entrega de arn codificador de imunogénio |
| WO2012170431A2 (en) * | 2011-06-06 | 2012-12-13 | Bluebird Bio, Inc. | Improved geneswitch systems |
| US11058762B2 (en) | 2011-07-06 | 2021-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| US20140141070A1 (en) | 2011-07-06 | 2014-05-22 | Andrew Geall | Liposomes having useful n:p ratio for delivery of rna molecules |
| WO2013006838A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| CA2840965C (en) | 2011-07-06 | 2021-03-02 | Novartis Ag | Cationic oil-in-water emulsions |
| EP3508220A1 (en) | 2011-08-31 | 2019-07-10 | GlaxoSmithKline Biologicals S.A. | Pegylated liposomes for delivery of immunogen-encoding rna |
| US8961995B2 (en) | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
| WO2014170493A2 (en) * | 2013-04-19 | 2014-10-23 | Novartis Ag | Alphavirus vector |
| WO2015051169A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| EA034103B1 (ru) | 2013-10-22 | 2019-12-27 | Транслейт Био, Инк. | СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК |
| EP3122774B1 (en) | 2014-03-25 | 2020-11-04 | Yale University | Uses of parasite macrophage migration inhibitory factors |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| KR20180004820A (ko) * | 2015-05-15 | 2018-01-12 | 큐어백 아게 | 적어도 하나의 mRNA 구성의 투여를 포함하는 신규 프라임-부스트 요법 |
| ES2964690T3 (es) | 2015-09-21 | 2024-04-09 | Trilink Biotechnologies Llc | Método para sintetizar ARN con caperuza 5' |
| KR20180074699A (ko) * | 2015-11-09 | 2018-07-03 | 이뮨 디자인 코포레이션 | 이종 핵산을 발현하는 rna 레플리콘의 발현 및 투여를 위한 레트로바이러스 벡터 |
| WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
| US12257352B2 (en) | 2016-06-20 | 2025-03-25 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| WO2018010815A1 (en) | 2016-07-15 | 2018-01-18 | Biontech Rna Pharmaceuticals Gmbh | Formulation for administration of rna |
| KR102718353B1 (ko) | 2016-10-17 | 2024-10-15 | 얀센 파마슈티칼즈, 인코포레이티드 | 재조합 바이러스 레플리콘 시스템 및 그의 용도 |
| US10487105B2 (en) | 2016-10-19 | 2019-11-26 | Arcturus Therapeutics, Inc. | Trinucleotide MRNA cap analogs |
| BR112019008481A2 (pt) | 2016-10-26 | 2020-03-03 | Curevac Ag | Vacinas de mrna de nanopartículas lipídicas |
| PE20191345A1 (es) | 2016-11-23 | 2019-09-30 | Gritstone Oncology Inc | Administracion viral de neoantigenos |
| JP7788787B2 (ja) | 2016-12-05 | 2025-12-19 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 遺伝子発現増強のための組成物および方法 |
| WO2018119163A1 (en) * | 2016-12-21 | 2018-06-28 | Payne Joseph E | Ionizable cationic lipid for rna delivery |
| US10383952B2 (en) * | 2016-12-21 | 2019-08-20 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| US20190374650A1 (en) | 2017-02-22 | 2019-12-12 | The Regents Of The University Of Michigan | Compositions and methods for delivery of polymer/biomacromolecule conjugates |
| WO2018160592A1 (en) | 2017-02-28 | 2018-09-07 | Arcturus Therapeutics, Inc. | Translatable molecules and synthesis thereof |
| MX2019013259A (es) | 2017-05-08 | 2020-01-13 | Gritstone Oncology Inc | Vectores de neoantigeno de alfavirus. |
| WO2018222926A1 (en) * | 2017-05-31 | 2018-12-06 | Ultragenyx Pharmaceutical Inc. | Therapeutics for glycogen storage disease type iii |
| ES3039647T3 (en) | 2017-05-31 | 2025-10-23 | Arcturus Therapeutics Inc | Synthesis and structure of high potency rna therapeutics |
| JP7311489B2 (ja) | 2017-07-28 | 2023-07-19 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 異種ｒｅｐＲＮＡ免疫化のための方法および組成物 |
| EP3727444A1 (en) | 2017-12-18 | 2020-10-28 | Intervet International B.V. | Swine influenza a virus vaccine |
| WO2019143949A2 (en) | 2018-01-19 | 2019-07-25 | Synthetic Genomics, Inc. | Induce and enhance immune responses using recombinant replicon systems |
| WO2020014654A1 (en) | 2018-07-13 | 2020-01-16 | The Trustees Of Indiana University | Recombinant rotavirus expression system and recombinant rotaviruses |
| EP3836963A2 (en) | 2018-08-17 | 2021-06-23 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions and uses thereof |
| US11026894B2 (en) | 2019-01-10 | 2021-06-08 | Massachusetts Institute Of Technology | Lipid nanoparticles and use thereof to deliver RNA polynucleotides |
| EP3942050A4 (en) | 2019-03-19 | 2023-02-22 | Arcturus Therapeutics, Inc. | PROCEDURE FOR THE PRODUCTION OF LIPID-COATED RNA NANOPARTICLES |
| US20220313813A1 (en) | 2019-06-18 | 2022-10-06 | Curevac Ag | Rotavirus mrna vaccine |
| GB201908729D0 (en) | 2019-06-18 | 2019-07-31 | Imp College Innovations Ltd | RNA construct |
| US20220313815A1 (en) | 2019-06-20 | 2022-10-06 | Janssen Sciences Ireland Unlimited Company | Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof |
| CN119770638A (zh) | 2019-09-30 | 2025-04-08 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| US12544437B2 (en) * | 2019-10-04 | 2026-02-10 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant AAV |
| US12194089B2 (en) * | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| WO2021160346A1 (en) * | 2020-02-13 | 2021-08-19 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| JP7832114B2 (ja) * | 2020-03-03 | 2026-03-17 | アークトゥラス・セラピューティクス・インコーポレイテッド | オルニチントランスカルバミラーゼ欠損症の治療のための組成物及び方法 |
| WO2021183563A1 (en) | 2020-03-09 | 2021-09-16 | Arcturus Therapeutics, Inc. | Coronavirus vaccine compositions and methods |
| TW202313967A (zh) | 2021-07-30 | 2023-04-01 | 美商亞克圖羅斯醫療公司 | Ｒｎａ疫苗 |
-
2021
- 2021-03-09 WO PCT/US2021/021572 patent/WO2021183563A1/en not_active Ceased
- 2021-03-09 EP EP21768525.4A patent/EP4117720A4/en active Pending
- 2021-03-09 CA CA3171231A patent/CA3171231A1/en active Pending
- 2021-03-09 EP EP21767978.6A patent/EP4117725A4/en active Pending
- 2021-03-09 CA CA3171219A patent/CA3171219A1/en active Pending
- 2021-03-09 WO PCT/US2021/021573 patent/WO2021183564A1/en not_active Ceased
- 2021-03-09 TW TW110108383A patent/TW202200605A/zh unknown
- 2021-03-09 JP JP2022554681A patent/JP2023517644A/ja active Pending
- 2021-03-09 AU AU2021233816A patent/AU2021233816A1/en active Pending
- 2021-03-09 JP JP2022554368A patent/JP2023519173A/ja active Pending
- 2021-03-09 US US17/196,890 patent/US11759515B2/en active Active
- 2021-03-09 US US17/196,889 patent/US11744887B2/en active Active
- 2021-03-09 AU AU2021236068A patent/AU2021236068A1/en active Pending
-
2023
- 2023-06-30 US US18/345,893 patent/US12220455B2/en active Active
- 2023-07-12 US US18/351,392 patent/US12390524B2/en active Active
-
2024
- 2024-12-04 US US18/969,110 patent/US20250161434A1/en active Pending
-
2025
- 2025-07-15 US US19/270,365 patent/US20260069677A1/en active Pending